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Abstract
Objectives—Osteoarthritis (OA) is a disease with a significant inflammatory component. The 
aim of this analysis was to determine the relationship between synovial fluid white cell count (SF 
WCC) and two parameters: disease severity and the reduction in knee pain after intra-articular 
steroid injection.
Methods—Subjects with painful knee OA were recruited for participation in an open label study 
of intra-articular steroid therapy. Information was obtained about knee pain using the KOOS 
questionnaire and a proportion of subjects had magnetic resonance imaging (MRI) performed. 
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Prior to injection with methylprednisolone acetate (80mg), the index knee joint was aspirated and 
the fluid obtained forwarded for assessment of SF WCC.
Results—Information on SF WCC was available in 55 subjects. An increase in white cell count 
category (< 100, 101–250 and > 250–1,000 cells/mm3) was associated with an increase in synovial 
tissue volume (p = 0.028) and with other MRI-based measures of disease severity. Also, with each 
category increase in SF WCC there was a greater mean reduction in KOOS pain score after steroid 
injection; ≤100 cells/mm3 12.5 (SD 19.9) [referent], 101–250 cells/mm3 21.3 (SD 20.6) [β 
coefficient 0.279 p=0.049 ] and 251–1000 cells/mm3 29.3 (SD 15.2) [β coefficient 0.320 
p=0.024].
Conclusion—Although within the ‘normal’ range, total synovial fluid white cell count appears 
to be a biomarker for MRI synovitis and may also predict response to anti-inflammatory treatment.
Osteoarthritis (OA) is increasingly recognised as a disease with a significant inflammatory 
component.[1] Recent studies suggest that up to 90% of subjects with knee OA have 
evidence of synovial thickening on magnetic resonance imaging (MRI).[2] Synovial 
thickening on MRI has been shown in persons with symptomatic knee OA to be correlated 
with macroscopic scoring of synovitis (r=0.61) and histologically with infiltration of 
inflammatory cells into the subsurface layers of synovium (r=0.54).[3] We have shown 
recently in symptomatic knee OA that there is a correlation between synovial tissue volume 
and pain severity.[4]
Synovial fluid (SF) white cell count (WCC) has long been recognised to have utility in 
assessment and diagnosis of arthritis.[5,6] However SF, WCC in osteoarthritis is typically 
designated as a non-inflammatory fluid (defined by Freemont as <1000 cells/mm3)[7] 
without any further stratification within that range.
Intra-articular steroid injections are a frequently used symptomatic treatment in knee OA but 
in clinical practice the response to therapy is mixed; some patients experience dramatic 
improvement in pain post injection whilst others derive little, if any, benefit. A wide variety 
of putative predictors of response to IA steroids have been evaluated previously though none 
have been found to be reliable predictors of treatment response (reviewed in [8]). 
Surprisingly, particularly given the frequency with which SF is obtained in research and 
clinical practice, the role of SF WCC as a potential predictor of treatment response or a 
marker of disease activity has not been fully evaluated.
We hypothesised that higher SF WCC levels within the non-inflammatory range, as a marker 
of low grade inflammation would be associated with increased synovial tissue volume and 
pain and might identify persons more likely to respond to an anti-inflammatory treatment. 
Using data from a recent open label trial of intra-articular corticosteroid injection (IACI).[4] 
The aim of this study was to determine the clinical and structural correlates of SF WCC in 
those with symptomatic knee OA.
MATERIALS and METHODS
120 men and women aged ≥ 40 years were recruited for participation in an open label study 
assessing the efficacy of IACI in knee OA and including assessment of structural change by 
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MRI (ISRCTN: 07329370). Eligibility including inclusion and exclusion criteria have been 
published previously.[4] We studied one knee per participant with a requirement that 
subjects had at least moderate knee pain for 48 hours in the preceding 2 weeks or scored >7 
on Knee Injury and Osteoarthritis Outcome Score (KOOS)[9] questions P2-P9. A further 80 
participated in an extension study which, because of costs, did not utilise MRI imaging but 
did not otherwise differ. Participants were required to have painful primary knee OA 
evidenced by radiographic, MRI or arthroscopy changes (Kellgren-Lawrence [K-L] score ≥2 
or typical changes of OA with at least cartilage loss). At baseline participants completed 
questionnaires including the KOOS, the pre-planned primary pain outcome and visual 
analogue scale (VAS) score for pain during a nominated activity the participant found most 
painful (VASNA). Participants in the main, though not the extension, study had a contrast 
enhanced MRI (CE-MRI) scan performed followed by arthrocentesis and injection of 80mg 
methylprednisolone acetate without local anaesthetic and were advised to rest for a day after 
the injection. Subjects were seen again usually within 2 weeks at which time they underwent 
repeat assessment including completion of KOOS and VASNA and had another CE-MRI. 
Participants provided written informed consent and this study was approved by the 
Leicestershire multicentre research ethics committee (reference 09/H0402/107).
Synovial fluid analysis
During arthrocentesis, SF, if present, was withdrawn and decanted into a 2ml lithium heparin 
tube. Those not immediately transferred to the laboratory were stored below 5°C and 
analysis was performed within 48 hours. Samples were processed in an experienced 
laboratory which provided a regional SF analysis service. Analysis was performed using the 
method described by Denton[10] with WCC determined using a Fuchs-Rosenthal counting 
chamber following staining with 0.01% w/v methyl violet 6b in normal saline or using an 
automated Cellometer Vision (PEQLAB Ltd, Sarisbury Green, UK) following staining with 
0.002% w/v acridine orange solution depending on equipment availability. Participants with 
a SF WCC >1500 cells/mm3 (n=2) were withdrawn from the trial due to concerns they 
might have primary inflammatory arthritis.
Magnetic resonance imaging assessment
At baseline and follow up participants in the MRI study underwent a CE-MRI of the knee 
performed using a 3T Phillips MRI. STV was determined by manual segmentation of the 
synovial tissue layer on the sagittal post-contrast T1W FS image by a single observer 
followed by computer image analysis as described previously.[4] The ICC for synovial 
volume was 0.94 (p<.001).[4] A sub-sample (N=101 in the MRI study) also underwent 
semi-quantitative assessment of cartilage (14 areas scored 0–6, maximum score 84), 
osteophytes (14 areas scored 0–7, maximum score 98) and BMLs (15 areas scored 0–3, 
maximum score 45) by an experienced radiologist using the Whole-Organ Magnetic 
Resonance Imaging Score (WORMS).[2] Semi-quantitative assessment of synovitis was 
performed at 7 regions, each scored (0–3) as described by Roemer et al[2]. Intra-reader 
reliability assessment was assessed by the same reader re-evaluating 19 films after an 
interval period with weighted kappas of 0.63 to 0.88 depending on the feature.
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Participants were divided into tertiles based on SF WCC; those with ≤100 cells/mm3, 101–
250 cells/mm3 and 251–1000 cells/mm3. At baseline, depending on the distribution of the 
variable, we used parametric (ANOVA) or non-parametric (Kruskal-Wallis) tests to 
determine the significance of differences in symptoms and structural change between 
groups. χ2 were used to test the differences in categorical data. We used linear regression to 
assess the association between SF WCC and within person change in pain and synovial 




A SF aspirate was obtained from 93 participants of whom 67 had SF analysis performed. Of 
these the median volume of synovial fluid was 4ml (IQR 2–9ml). Compared to those who 
had synovial fluid analysis, those who did not were not significantly different in terms of 
their age (66.6 years vs 62.6 years), and pain at baseline (KOOS : 44.2 vs 45.7 ; NA-VAS 
6.8 vs 7.0). The laboratory reported a precise SF WCC for 47 samples (70.1% of all SF 
analysed) with the remainder reported as either ‘<100’ (N=8, 11.9%) or ‘<500’ (N=12, 
17.9%) cells/mm3. Due to the uncertainty about the WCC estimate; those reported as ‘<500 
cells/mm3’ were excluded from further analysis, leaving 55 subjects; 37 with MRI data and 
18 without. The mean age of those 55 subjects with data on SF was 61 years (SD=10.3) and 
just under two thirds were men. The majority of participants had a K-L grade of 2 or 3. 
Mean KOOS pain at baseline was 46.6 (SD=15.6), see Table 1.
Association between SF WCC, knee pain and structural parameters
We found no significant association between SF WCC and either age, pain at baseline as 
assessed by KOOS or VASNA, or with disease severity as assessed by K-L score. In contrast 
there was a significant increase in synovial tissue volume with increasing WCC category; 
also an increase in whole knee semi-quantitative scoring of synovitis, cartilage loss, and 
BML score with increasing WCC category. There was, however, no association with 
osteophyte score, see Table 2.
SF WCC and change in pain and structure following steroid injection
Subjects were reviewed a median of 8 days (interquartile range 8 to 14 days) following 
baseline assessment. Compared to those with a WCC < 100 cells/mm3 there was a greater 
within person reduction in KOOS score in those with a WCC between 101–250 cells/mm3 
(β coefficient 0.279, p=0.049) and 251–1000 cells/mm3 (β coefficient 0.320, p=0.024), see 
Table 3. Further adjustment for the amount of synovial fluid removed did not affect the 
significance of the results. A similar trend of greater pain reduction with increasing synovial 
fluid WCC was observed for VASNA but this did not reach statistical significance (≤100 
cells/mm3 referent; 101–250 cells/mm3, β coefficient -0.242, p=0.107; 251–1000 cells/mm3, 
β coefficient -0.272, p=0.072). Increasing WCC was associated with a greater within person 
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change in synovitis as measured both quantitatively and semi-quantitatively though the 
association did not attain statistical significance.
DISCUSSION
This is the first study to assess the association between SF WCC and knee joint structure 
assessed by MRI in knee OA. Even though all participants in the analysis had SF WCC 
within the ‘normal’ range, our data showed that increasing SF WCC was correlated with 
more severe knee OA and also synovitis as defined by synovial tissue volume. Additionally 
those with higher SF WCC at baseline experienced greater reduction in knee pain following 
an intra-articular steroid injection.
Our finding of an association between SF WCC and synovitis at baseline assessed either 
quantitatively or semi-quantitatively is consistent with findings of an increased SF WCC and 
other measures of inflammation in primary inflammatory arthritides. [5,6,10,11] We found 
no association of SF WCC with K-L grade though the numbers of those with more severe 
disease (N=3 for K-L 4) was small. To our knowledge there are only two other studies that 
have looked at the association between SF WCC and K-L grade; neither showed evidence of 
any association [12,13].
We also identified an association between increasing baseline SF WCC and the reduction in 
pain assessed by KOOS score following intra-articular steroid injection. Those is the highest 
tertile of SF WCC experienced a greater than two fold greater reduction in pain assessed by 
either KOOS or VASNA compared to those in the lowest. These findings suggest that SF 
WCC could have a role in predicting treatment response. This or other measures of synovial 
inflammation may even facilitate treatment stratification. One previous study reported no 
association between baseline WCC and change in VAS pain following intra-articular steroid 
injection in knee OA, though only 16 subjects were studied .[13]
There are a number of limitations which need to be considered in interpreting our data. This 
study was a post-hoc analysis using existing data and the number of participants included in 
this analysis is small (N=55 with 37 contributing MRI data). Some caution is therefore 
required in interpretation. Our primary rationale for assessing SF WCC was to identify and 
exclude participants with an alternate diagnosis. Therefore during the conduct of this study 
we accepted reporting of SF WCC as either ‘<100’ or ‘<500’ cell/mm3 as these were below 
the exclusion criteria cut off. However, the manner in which SF WCC was reported led to a 
reduction in our sample size, due to the exclusion of from participants with WCC reported 
as ‘<500’ cells/mm3, and prevented analysis using SF WCC as a continuous variable. Both 
of these limitations served to reduce the power of the study. Further studies with larger 
number of participants are required to confirm the findings.
The clinical utility of our findings remains uncertain. It is possible that a high SF WCC 
within the normal range may identify persons more likely to benefit from an intra-articular 
steroid injection and even from other treatments targeted to joint inflammation. Our results 
highlight the need for further research to assess the potential value of SF WCC in OA. SF 
WCC may be an overlooked, yet easily measurable,[14] marker of OA disease severity or 
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even a predictor of treatment response. These findings may important implication in both the 
design of future research studies and clinical practice.
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Table 1
Baseline characteristics for all subjects
Variable Statistic
Mean (SD)
Age (years) 61.0 (10.3)
Gender N (%)
  Male 36 (65.5)
  Female 19 (34.6)
Maximal Kellgren-Lawerence score in either
patellofemoral or tibiofemoral compartment N (%)
  2 19 (37.3)
  3 29 (56.9)
  4 3 (5.9)
Pain Mean (SD)
  KOOS pain* 46.6 (15.6)
  Nominated activity VAS* 7.0 (1.8)
MRI Volumetric Assessment Median (IQR)
  Synovial tissue volume (mm3) 9667 (6320–13231)
Whole knee semi-quantitative assessment
  Synovitis† 15 (12–16)
  Bone marrow lesion‡ 6 (3–9)
  Cartilage‡ 11.5 (6–18)
  Osteophytes ‡ 36 (20–53)
*
KOOS scored from 100 (no pain) to 0 (extreme pain), Nominated activity VAS scored from 0 (no pain) - 10 (extreme pain). Abbreviations: KOOS 
- Knee Injury and Osteoarthritis Outcome score,
†
Sum of 7 regions (each scored 0–3)
‡
Assessed using the Whole Organ Magnetic Imaging Score. Whole knee scores calculated as the sum of individual compartment scores
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